The changing landscape of liver cancer clinical research will drive the way treatment strategies evolve in the coming years, but what key trends are making their impact? Some of the main trends are moving towards immunotherapies especially immune checkpoint inhibitors (Nivolumab, Pembrolizumab & Atezolizumab). Immunotherapies, which work by blocking PD-1/PD-L1 and other proteins that tumors use to suppress the immune system response are being studied extensively due to their ability to enhance the activity of cancer-specific immunity.
Another key trend is the use of combination therapy, primarily combining immunotherapy with VEGF inhibitors such as Bevacizumab or Sorafenib. These combinations are designed to enhance efficacy by attacking tumors at two fronts: they target tumor angiogenesis (blood vessel formation) and stimulate immune activity. Clinical trials now suggest that this immunotherapy is promising in improving survival rates and slowing progression of the disease, particularly for advanced hepatocellular carcinoma (HCC) [3].
Focus on targeted therapies, especially tyrosine kinase inhibitors (TKIs) such as Sorafenib and Lenvatinib. While these drugs have been the backbone of treatment in advanced liver cancer for years, new agents and combination strategies are being investigated to build upon this progress through ongoing clinical trials.
In addition, oncolytic virus therapy has been attracting attention for its use of modified viruses that infect and kill cancer cells while inducing systemic antitumor immunity. While this area of research is still in its early stages, these therapies offer a new approach to treat patients that will be complimentary with existing treatments.
Such trends are a part of the larger thrust towards personalized medicine in liver cancer, aiming to develop more effective and individualized therapies so that patient survival rates increase.
The following table outlines the primary mechanisms of action being investigated in liver cancer clinical trials, along with key drugs and the number of trials associated with each mechanism.
|
Mechanism of Action |
Key Drugs |
|
Immune Checkpoint Inhibition |
Nivolumab, Pembrolizumab, Atezolizumab |
|
VEGF/VEGFR Inhibition (Angiogenesis Inhibition) |
Bevacizumab, Sorafenib, Lenvatinib |
|
Tyrosine Kinase Inhibition |
Sorafenib, Lenvatinib, Cabozantinib |
|
Combination Therapy (Immune Checkpoint + VEGF Inhibitors) |
Atezolizumab + Bevacizumab, Pembrolizumab + Lenvatinib |
|
Oncolytic Virus Therapy |
Talimogene Laherparepvec (T-VEC) |
In the US and worldwide, there is a significant burden of liver cancer. It is also estimated that the United States will see about 41,630 new cases of liver cancer in 2024 and there are expected to be about 29,840 deaths from this malignancy due to its high lethality. Liver cancer is the sixth most common type of cancer around the world and has been on the rise steadily
Liver cancer — Being among the most burdensome cancers worldwide, liver cancer impairs health disproportionately in certain populations such as men and compared to women. In the Great Plains states of the US, it has an age-adjusted incidence ratio as high as 6.8/100,000 people. Risk factors include chronic hepatitis B and C infections, alcohol use, nonalcoholic fatty liver disease (NAFLD), and cirrhosis.
Clinical trials are underway, which will be vital for the future treatment of liver cancer as incidence is on the rise. Research is now focused on new combinations with first-generation immune checkpoint inhibitors and VEGFR inhibitors leading the way for improving patient outcomes. These treatments will be an important driver for a substantial expansion of the liver cancer market and new drug approvals should support growth in the pharmaceutical industry.
Nevertheless, the cost of these new therapies is high and may potentially limit its spread into low-income areas. This underscores the need for research in cost-effective interventions, such as biosimilar development with economic evaluation. However, this will require the assistance of regulatory agencies that are agile enough to get these therapies on the market quickly and safely.
Table of Contents
1.1 Overview of Liver Cancer
1.2 Importance of Clinical Trials in Liver Cancer Research
2.1 Incidence and Prevalence
2.2 Demographic Distribution (Age, Gender, and Risk Factors)
2.3 Mortality Rates and Survival Statistics
3.1 Overview of Ongoing Clinical Trials
3.2 Geographical Distribution of Research Efforts
4.1 Immune Checkpoint Inhibition
4.2 VEGF/VEGFR Inhibition (Angiogenesis Inhibition)
4.3 Tyrosine Kinase Inhibition
4.4 Combination Therapy (Immune Checkpoint + VEGF Inhibitors)
4.5 Oncolytic Virus Therapy
5.1 Phase-wise Distribution of Trials
5.2 Insights into Progression and Focus Across Different Phases
6.1 Potential New Standards of Care
6.2 Impact on Regulatory and Market Dynamics
7.1 Summary of Key Findings
7.2 Future Directions in Liver Cancer Research
8.1 Glossary of Terms
8.2 List of Abbreviations
8.3 References and Data Sources
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
